NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NKTR-255’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NKTR-255 overview

NKTR-255 is under development for the treatment of relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, metastatic urothelial cancer, cancer immunotherapies, metastatic head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), colon carcinoma, metastatic cervical cancer, metastatic anal squamous cell carcinoma, metastatic cutaneous squamous cell carcinoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Burkitt lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, non-small cell lung cancer, primary mediastinal large b-cell lymphoma and infectious disease. It is a recombinant protein. It is administered through intravenous route. It is developed based on polymer conjugation technology. It was also under development for lung cancer.

See Also:

Nektar Therapeutics overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

For a complete picture of NKTR-255’s drug-specific PTSR and LoA scores, buy the report here.